Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma.
Jessica S W BorgersTineke J van WesemaelKyra A GeldermanTheo RispensElizabeth M E VerdegaalDirk J A R MoesCatharina M KorseEllen H W KapiteijnMarij J P WeltersSjoerd H Van der BurgWinan J van HoudtJohannes V van ThienenJohn B A G HaanenDiane van der WoudePublished in: Journal for immunotherapy of cancer (2024)
The presence of autoantibodies prior to anti-PD-1 therapy is associated with irAEs in patients with melanoma. Both baseline positivity and seroconversion of anti-thyroid antibodies were strongly associated with thyroid dysfunction. This association was stronger in women, with all women who were baseline positive developing thyroid dysfunction.